PDS Biotechnology Corporation (PDSB) |
2.645 -0.255 (-8.79%) 04-19 16:00 |
Open: | 2.86 |
High: | 2.915 |
Low: | 2.59 |
Volume: | 881,343 |
Market Cap: | 97(M) |
PE Ratio: | -1.9 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 5.00 |
Resistance 1: | 4.08 |
Pivot price: | 3.21 |
Support 1: | 2.59 |
Support 2: | 2.15 |
52w High: | 10.27 |
52w Low: | 2.59 |
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
EPS | -1.390 |
Book Value | 0.790 |
PEG Ratio | -0.03 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -39.5 |
Return on Equity (ttm) | -122.5 |
Sat, 30 Mar 2024
PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who ... - Yahoo Finance
Thu, 28 Mar 2024
PDS Biotechnology stock target cut, retains buy rating on ongoing clinical trials - Investing.com
Thu, 28 Mar 2024
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 27 Mar 2024
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023 - InvestorPlace
Wed, 27 Mar 2024
PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 13 Mar 2024
The 3 Most Undervalued Biotech Stocks to Buy in March 2024 - InvestorPlace
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |